Preferences help
enabled [disable] Abstract
Number of results
2014 | 9 | 2 | 285-291
Article title

Differences on the prevalence of cervical HPV between Lithuania and Belarus

Title variants
Languages of publication
In some countries the cervical cancer incidence and mortality rates are much higher compared to the European average. The differences of HPV and its type prevalence between countries and regions influence cervical cancer incidence and mortality. Regarding the differences in cervical cancer incidence and mortality in Lithuania and Belarus, the aim of this study was to describe HPV infection level and HPVs type distribution among two study groups of patients with moderate or severe cervical intraepithelial neoplasia (CIN2-3) and cervical cancer. Our data shows that 74.2% [95% CI: 63.64÷84.76] of Lithuanian patients with cervical cancer and 85.6% [95% CI: 85.53÷92.85] of the study group with CIN2-3 were HPV positive, while in the study groups of Belarusian patients HPV infection was detected in 92.6% [95% CI, 74.25÷98.71] and 65.4% [95% CI, 44.36÷82.06] cases respectively. HPV 16 was the most prevalent type in Lithuanian as well as in Belarusian patients of the study groups. HPV 18 in Lithuanian patients of the study group with cervical cancer was identified in 10.2% [95% CI: 1.73÷18.67] and in the study group with CIN2-3 - in 2.6% [95% CI: 0.95÷6.15] of cases. HPV 18 was not detected in Belarusian patients of both groups.

Physical description
1 - 4 - 2014
13 - 2 - 2014
  • Institute of Oncology, Vilnius University, Santariskiu str. 1, LT-08660, Vilnius, Lithuania
  • Institute of Oncology, Vilnius University, Santariskiu str. 1, LT-08660, Vilnius, Lithuania
  • N.N. Alexandrov National Cancer Center, Lesnoj, 223040, Minsk region, Belarus
  • N.N. Alexandrov National Cancer Center, Lesnoj, 223040, Minsk region, Belarus
  • N.N. Alexandrov National Cancer Center, Lesnoj, 223040, Minsk region, Belarus
  • N.N. Alexandrov National Cancer Center, Lesnoj, 223040, Minsk region, Belarus
  • [1] Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. GLOBOCAN 2008 v2.0, Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 10 [Internet]. Lyon, France: International Agency for Research on Cancer, 2010. Available from:, accessed on day/month/year
  • [2] Castellsagué X, Díaz M, de Sanjosé S, Muñoz N, Herrero R, Franceschi S, et al. Worldwide human papillomavirus etiology of cervical adenocarcinoma and its cofactors: implications for screening and prevention. J Nati Cancer Inst. 2006;98(5):303–315[Crossref]
  • [3] Bosch FX, Lorincz A, Muñoz N, Meijer CJ, Shah KV: The causal relation between human papillomavirus and cervical cancer. J Clin Pathol 2002;55(4):244–265[Crossref]
  • [4] Munoz N, Bosch FX, de Sanjose S, Herrero R, Castellsague X, Shah KV, Snijders PJ, Meijer CJ: Epidemiologic classification of human papillomavirus types associated with cervical cancer. N Engl J Med 2003;348:518–527[Crossref]
  • [5] Munoz N, Castellsague X, de Gonzalez AB, Gissmann L: Chapter 1: HPV in the etiology of human cancer. Vaccine 2006;24(Suppl 3):1–10[Crossref]
  • [6] Steben M, Duarte-Franco E. Human papillomavirus infection: epidemiology and pathophysiology. Gynecol Oncol 2007;107:S2–S5[WoS][Crossref]
  • [7] Stanley M. Pathology and epidemiology of HPV infection in females. Gynecol Oncol 2010;117(2):S5–S10[Crossref][WoS]
  • [8] Anttila A, Ronco G: Description of the national situation of cervical cancer screening in the member states of the European Union. Eur J Cancer 2009;45(15):2685–2708[Crossref]
  • [9] Arbyn M, Anttila A, Jordan J, Ronco G, Schenck U, Segnan N, Wiener H, Herbert A, von Karsa L: European Guidelines for Quality Assurance in Cervical Cancer Screening. Second Edition-Summary Document. Ann Oncol 2010;21(3):448–458[Crossref][WoS]
  • [10] WHO/Europe, European HFA Database, January 2012
  • [11] Popendikyte V, Gulbinovic I, Paulauskiene V, Paulauskas D. High risk human papilloma virus detection and genotyping by multiplex PCR. Lietuvos akuserija ir ginekologija (Lithuanian Obstetrics and Gynecology) 2000;11:348–352
  • [12] Cancer in Lithuania 2009. Institute of Oncology, Vilnius University. Cancer registry data, 2011 (available in
  • [13] Gudlevicienė Z, Didziapetriene J, Ramael M, Uleckiene S, Valuckas KP: Human papillomavirus and p53 polymorphism in Lithuanian cervical cancer patients. Gynecol Oncol 2006;102(3):530–533
  • [14] Gudlevicienė Z, Didziapetriene J, Suziedelis K, Lapkauskaite L. Investigation of human papillomavisur its types and variants. Medicina (Lithuania) 2005;41(11):910–915
  • [15] Istomin YP, Lapzevich TP, Chalau VN, Shliakhtsin SV, Trukhachova TV. Photodynamic therapy of cervical intraepithelial neoplasia grades II and III with Photolon. Photodiagnosis Photodyn Ther 2010;7(3):144–151[WoS][Crossref]
  • [16] Kulmala SM, Shabalova IP, Petrovitchev N, Syrjänen KJ, Gyllensten UB, Syrjänen SM; NIS Study Group. Prevalence of the most common high-risk HPV genotypes among women in three new independent states of the former Soviet Union. J Med Virol 2007;79(6):771–781[Crossref]
  • [17] Wężowska M, Giedrys-Kalemba S, Szymaniak L, Borowiec-Chłopek Ż, Konstanty-Kurkiewicz V, Menkiszak J. Risk factors for cervical cancer among young women. Central European Journal of Medicine. Central European Journal of Medicine 2012, DOI: 10.2478/s11536-012-0063-3 [Crossref]
  • [18] IARC Monographs on the Evaluation of Carcinogenic Risks to Humans. Vol. 90, Human Papillomaviruses, IARC Monographs 2007
Document Type
Publication order reference
YADDA identifier
JavaScript is turned off in your web browser. Turn it on to take full advantage of this site, then refresh the page.